Poolbeg Pharma (LON:POLB) Trading Up 2% – Should You Buy?

Poolbeg Pharma PLC (LON:POLB) was up 2% during mid-day trading on Friday . The company traded as high as GBX 7.79 ($0.10) and last traded at GBX 7.75 ($0.10). Approximately 1,244,478 shares changed hands during mid-day trading, a decline of 27% from the average daily volume of 1,711,140 shares. The stock had previously closed at GBX 7.60 ($0.10).

Poolbeg Pharma Stock Up 2.0 %

The firm has a 50 day moving average of GBX 8.55 and a 200-day moving average of GBX 11.31. The company has a market cap of £38.75 million, a P/E ratio of -775.00 and a beta of 2.11.

Poolbeg Pharma Company Profile

Poolbeg Pharma plc operates as a biopharmaceutical company in the United Kingdom. It develops POLB 001, a p38 MAP Kinase inhibitor for the treatment of severe influenza; POLB 002, an in­licensed first­in­class broad spectrum RNA­based immunotherapy for respiratory virus infections; and POLB 003, an intramuscular vaccine to prevent Melioidosis.